Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04120233 · ClinicalTrials.gov registry record · Phase 1
MW151-101: First-in-human Study of MW151
A Phase 1 study, sponsored by Linda Van Eldik.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04120233 is a Phase 1 study that has completed, run by Linda Van Eldik. The registered enrollment target is 40 participants.
The verdict
NCT04120233, a Phase 1 study, has completed, sponsored by Linda Van Eldik.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
MW01-2-151SRM (=MW151), a small molecule, is being developed for the treatment of cognitive disorders. The development program is based on nonclinical evidence that MW151 improves neurocognitive outcomes in animal models of radiation-induced cognitive impairment, Alzheimer's disease, and other central nervous system (CNS) disorders. The present study will provide safety and pharmacokinetic (PK) information on single ascending doses to support decisions for continued clinical development.
Interventions
- DRUG Placebo
- DRUG MW151, 10mg
- DRUG MW151, 20mg
- DRUG MW151, 40mg
- DRUG MW151, 80mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-10-22 |
| Est. Completion | 2021-09-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04120233
The ClinicalTrials.gov registry entry for NCT04120233 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Linda Van Eldik, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT04120233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04120233 about?
NCT04120233 is a clinical study titled "MW151-101: First-in-human Study of MW151". MW01-2-151SRM (=MW151), a small molecule, is being developed for the treatment of cognitive disorders. The development program is based on nonclinical evidence that MW151 improves neurocognitive outcomes in animal models of radiation-induced cognitive impairment, Alzheimer's disease, and other centr...
What is the current status of trial NCT04120233?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-10-22. Estimated completion is 2021-09-16.
What interventions are being tested in trial NCT04120233?
The interventions under investigation include: Placebo (DRUG), MW151, 10mg (DRUG), MW151, 20mg (DRUG), MW151, 40mg (DRUG), MW151, 80mg (DRUG).
Who is sponsoring clinical trial NCT04120233?
This trial is sponsored by Linda Van Eldik, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.